Peter Jackson, Infex Therapeutics executive director

Scoop: In­fec­tious dis­ease biotech eyes $25M Se­ries A to ad­vance an­ti­body for chron­ic lung in­fec­tion

In­fex Ther­a­peu­tics is plan­ning to raise up to £20 mil­lion ($25 mil­lion) in a Se­ries A round with an eye to pro­gress­ing its lead as­set — which it in-li­censed from Japan­ese phar­ma Sh­iono­gi — through to Phase IIb in chron­ic Pseudomonas aerug­i­nosa in­fec­tion in peo­ple with non-cys­tic fi­bro­sis bronchiec­ta­sis (NCFB).

“We’re look­ing to build a book of in­vestors through the end of quar­ter one [in 2024] and in­to quar­ter two,” ex­ec­u­tive di­rec­tor Pe­ter Jack­son told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.